Dr. Robert N. Taub
Dr. Robert N. Taub, the director of Columbia University’s Mesothelioma Center in New York City, has devoted his career to developing treatments for pleural and peritoneal mesothelioma.
Taub has developed one of the most extensive peritoneal mesothelioma practices in the world and one of the most widely used protocols for the disease. The technique, called intracavitary chemotherapy, begins when the cancerous tissue is removed and then calls for recurring doses of chemotherapy distributed directly into the abdominal area for 12 weeks. Taub also works as a medical oncologist and hematologist at New York-Presbyterian/Columbia University Medical Center.
Today, Taub is working to developing a treatment procedure using intracavitary chemotherapy for multimodal treatment of mesothelioma.
Connect with Top Doctors and Cancer Centers
Get help connecting with a mesothelioma doctor or treatment center near you right now!
Mesothelioma Specialist in New York
New York is considered the birthplace of the asbestos industry because it was used so widely as New York City was growing. Across the New York coastline, asbestos was widely used in shipyards, including the GMD Shipyard and the Brooklyn Navy Yard. In the more rural areas, it was used in home and building construction. More recently, the deadly material was widely disbursed following the collapse of the World Trade Center during the 9/11 terrorist attacks.
It is imperative for anyone diagnosed with mesothelioma to seek the help of a mesothelioma specialist. If you or a loved one have been diagnosed with mesothelioma, contact us today for quick access to a local mesothelioma specialist.
What are Taub’s specialties
Taub has an interest in both pleural and peritoneal mesotheliomas. Over the years, he as led several clinical trials to research the effectiveness of multimodal therapy, which is commonly used today. Taub has a special interest in translational studies in mesothelioma and soft-tissue sarcoma.
In 2008, he began a trial that looked at the effectiveness of targeted radiation in pleural mesothelioma patients. In 2014, Taub and his colleagues completed a trial that research the pleural mesothelioma tumor response to the chemotherapy drugs Velcade and Eloxatin. Trial results are not available yet.
What is Taub’s background
Taub graduated from Yale University School of Medicine in 1961 and went on to finish his medical studies at New England Medical Center in 1966. He also earned a Ph.D. in 1969 from London University in the United Kingdom.
Taub has served on the editorial board of several medical specialty publications, including Blood and Transplantation. He has written or co-authored more than 140 peer-reviewed journal articles and taken part of many clinical trials. He is a member of the Mesothelioma Applied Research Foundation’s scientific advisory board.
NewYork-Presbyterian. Robert N. Taub, MD. Retrieved from http://nyp.org/physician/rntaub/
Columbia University Medical Center. Division of Hematology/Oncology. Robert Taub, M.D., Ph.D. Retrieved from http://www.cumc.columbia.edu/hematology-oncology/about_us/robert_taub